Danaher Corporation (NYSE:DHR) Announces Quarterly Dividend of $0.40

Danaher Corporation (NYSE:DHR) declared a quarterly dividend on Tuesday, September 15th. Shareholders of record on Wednesday, September 30th will be paid a dividend of 0.40 per share by the conglomerate on Friday, October 30th. This represents a c) dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Wednesday, September 30th.

Danaher has increased its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 2 years. Danaher has a payout ratio of 18.7% meaning its dividend is sufficiently covered by earnings. Research analysts expect Danaher to earn $9.26 per share next year, which means the company should continue to be able to cover its $1.60 annual dividend with an expected future payout ratio of 17.3%.

Danaher Trading Up 2.9%

DHR stock opened at $209.23 on Wednesday. The company has a market capitalization of $147.09 billion, a PE ratio of 37.16, a price-to-earnings-growth ratio of 2.53 and a beta of 0.78. Danaher has a one year low of $160.93 and a one year high of $242.80. The company’s 50 day moving average price is $203.15 and its two-hundred day moving average price is $191.90. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same period in the previous year, the business posted $0.77 EPS. The business’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, analysts predict that Danaher will post 8.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DHR. Evercore reissued an “outperform” rating and issued a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. HSBC reduced their price objective on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Weiss Ratings raised Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, July 15th. UBS Group initiated coverage on Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price for the company. Finally, Citigroup started coverage on Danaher in a research report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $228.91.

Danaher Company Profile

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.